NCT05377580View on ClinicalTrials.gov

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

September 30, 2025

Conditions
Ulcerative Colitis (UC)
Interventions
DRUG

Period 1 IBI112 Placebo

Intravenous Injection

DRUG

Period 2 IBI112 dose 3

Subcutaneous injections

DRUG

Period 1 IBI112 dose 1

Intravenous Injection

DRUG

Period 1 IBI112 dose 2

Intravenous Injection

DRUG

Period 2 IBI112 dose 4

Intravenous Injection

DRUG

Period 2 IBI112 Placebo

Subcutaneous injections

Trial Locations (1)

510080

First Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY